03:11
Daiwa: İlaç Ming Biyoloji hedef fiyatını %17 artırdı, "Al" tavsiyesini korudu
Daiwa's report states that the target price of WuXi Biologics has been raised to 27 Hong Kong dollars, with forecasted revenue growth from 2024 to 2026, an increase in the number of new projects in 2024, and an expected 6% year-on-year revenue growth and 11% profit increase. The revenue in the second half of 2024 is expected to grow by 11% year-on-year, and the gross profit margin is expected to improve to 42.9%.
- 4
- 2

